Financial objectives

Within the next three years, FIT Biotech is aiming at licensing its technology to partners who are able to take responsibility for the product development and the future commercialisation of the drugs. The company’s revenue model is based on the signing fees and milestone payments from the targeted licence agreements, as well as royalties. The future operating result of FIT Biotech is dependent on the licence fees from new agreements targeted in the field of gene therapy in particular, as well as the payments based on agreements following the heads of agreements already signed by the company being realised as planned.

Due to delays in the preclinical studies aiming at making potential license agreements related to the gene-based treatments and delays in preliminary studies into poultry vaccines, the Company assesses that its operating profit for 2016 will be negative.